Regorafenib Deemed Not Cost-Effective for Metastatic CRC

This article originally appeared here.
Share this content:
Regorafenib Deemed Not Cost-Effective for Metastatic CRC
Regorafenib Deemed Not Cost-Effective for Metastatic CRC

MONDAY, Sept. 21, 2015 (HealthDay News) -- Given its high cost, regorafenib provides little added benefit as a third-line treatment for metastatic colorectal cancer, according to a study published online Aug. 24 in the Journal of Clinical Oncology.

Daniel A. Goldstein, M.D., from Emory University in Atlanta, and colleagues developed a Markov model to compare the cost-effectiveness of regorafenib with that of a placebo in the third-line treatment of metastatic colorectal cancer. Medicare 2014 reimbursement rates were used to assess drug costs.

The researchers found that regorafenib provided an additional 0.04 quality-adjusted life-years (QALYs) (0.13 life-years) at a cost of $40,000, resulting in an incremental cost-effectiveness ratio of $900,000 per QALY. In univariable and probabilistic sensitivity analyses, the incremental cost-effectiveness ratio for regorafenib was >$550,000 per QALY.

"Regorafenib provides minimal incremental benefit at high incremental cost per QALY in the third-line management of metastatic colorectal cancer," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »